LSS in pirfenidone trial. This figure shows the results of the LSS, which assess symptoms associated with cGVHD across 7 domains: skin, energy, lung, eye, nutrition, mouth, and psychological well-being. The questionnaire contains 30 items, each rated on a 5-point Likert scale. Scores range from 0 to 100, with higher scores indicating more severe symptoms of cGVHD. MCID: a change of more than 5 points is considered clinically significant, denoted by #. Questionnaires were administered at baseline and 12 months after pirfenidone treatment. The data are presented as mean scores with the standard error of the mean, and analyzed for significance using paired t tests. Statistically significant differences (P < .05) are indicated by ∗∗. Psych, psychological.
Figure 7.

LSS in pirfenidone trial. This figure shows the results of the LSS, which assess symptoms associated with cGVHD across 7 domains: skin, energy, lung, eye, nutrition, mouth, and psychological well-being. The questionnaire contains 30 items, each rated on a 5-point Likert scale. Scores range from 0 to 100, with higher scores indicating more severe symptoms of cGVHD. MCID: a change of more than 5 points is considered clinically significant, denoted by #. Questionnaires were administered at baseline and 12 months after pirfenidone treatment. The data are presented as mean scores with the standard error of the mean, and analyzed for significance using paired t tests. Statistically significant differences (P < .05) are indicated by ∗∗. Psych, psychological.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal